Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Faraz Ali Insider Profile
4 Followers
Faraz Ali, Chief Business Officer at RegenXBio, holds ― shares in RegenXBio (Ticker: RGNX), holds 188.33K shares in Tenaya Therapeutics (Ticker: TNYA). Most recently, Faraz Ali ― shares of RegenXBio on ― for an estimated value of ―.
Profitable Transactions
3 out of 3 Profitable Transactions
Average Return
+42.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Faraz Ali holds in companies
Most Profitable Insider Trade
The most profitable trade made by Faraz Ali
Faraz Ali's Trading History
RegenXBio
―
Chief Business Officer
―
―
Tenaya Therapeutics
Aug 16, 2024
CEO, Director
Informative Sell
28.17K
$365.36K
List of latest transactions for each holding click on a transaction to see Faraz Ali's performance on stock
You May Also Like
Faraz Ali insider profile FAQ
What is the percentage of profitable transactions made by Faraz Ali?
The percentage of profitable transactions made by Faraz Ali is 100%.
What is the average return per transaction made by Faraz Ali?
The average return per transaction made by Faraz Ali is 42.60%.
What stocks does Faraz Ali hold?
Faraz Ali holds: RGNX, TNYA stocks.
What was Faraz Ali’s latest transaction?
Faraz Ali latest transaction was an Uninformative Buy of ―.
What was Faraz Ali's most profitable transaction?
Faraz Ali’s most profitable transaction was an Informative Sell of TNYA stock on February 16, 2024. The return on the trade was 69.30%.
What is Faraz Ali's role in RegenXBio?
Faraz Ali's role in RegenXBio is Chief Business Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.